{"transactions":[{"id":735244,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-17T22:02:08.000Z","date":"2026-06-15","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service."}],"balance_after":150000,"derivative":{"exercise_price":18.71,"expiration_date":"2036-06-15","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001104659-26-075254","document":"tm2618042-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000110465926075254/tm2618042-6_4seq1.xml","form_type":"4"}},{"id":1170516,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-17T20:01:17.000Z","date":"2025-04-15","kind":"grant","planned":false,"acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the underlying shares of common stock on March 17, 2025, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal month installments over 36 months thereafter, subject to continued service."}],"balance_after":400000,"derivative":{"exercise_price":8.72,"expiration_date":"2035-04-14","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001104659-25-035996","document":"tm2512517-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000110465925035996/tm2512517-1_4seq1.xml","form_type":"4"}},{"id":1262291,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2025-02-20T01:05:09.000Z","date":"2025-02-15","kind":"exercise","planned":true,"acquired":false,"shares":8907,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":26718,"derivative":{"underlying":"Common Stock","underlying_shares":8907},"source":{"system":"sec-edgar","filing":"0000950170-25-023569","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000095017025023569/ownership.xml","form_type":"4"}},{"id":1262290,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2025-02-20T01:05:09.000Z","date":"2025-02-15","kind":"exercise","planned":true,"acquired":false,"shares":2969,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":23750,"derivative":{"underlying":"Common Stock","underlying_shares":2969},"source":{"system":"sec-edgar","filing":"0000950170-25-023569","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000095017025023569/ownership.xml","form_type":"4"}},{"id":1262289,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-02-20T01:05:09.000Z","date":"2025-02-18","kind":"sale","planned":true,"acquired":false,"shares":4416,"price":0.8105,"value":3579.168,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 11, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.81 to $0.8376, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":39875,"source":{"system":"sec-edgar","filing":"0000950170-25-023569","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000095017025023569/ownership.xml","form_type":"4"}},{"id":1262288,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-02-20T01:05:09.000Z","date":"2025-02-15","kind":"exercise","planned":true,"acquired":true,"shares":8907,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":44291,"source":{"system":"sec-edgar","filing":"0000950170-25-023569","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000095017025023569/ownership.xml","form_type":"4"}},{"id":1262287,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-02-20T01:05:09.000Z","date":"2025-02-15","kind":"exercise","planned":true,"acquired":true,"shares":2969,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":35384,"source":{"system":"sec-edgar","filing":"0000950170-25-023569","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000095017025023569/ownership.xml","form_type":"4"}},{"id":1275121,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-11T21:15:04.000Z","date":"2025-02-07","kind":"grant","planned":false,"acquired":true,"shares":650000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 25% of the shares on February 7, 2026. The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":650000,"derivative":{"exercise_price":0.782,"expiration_date":"2035-02-06","underlying":"Common Stock","underlying_shares":650000},"source":{"system":"sec-edgar","filing":"0000950170-25-017911","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000095017025017911/ownership.xml","form_type":"4"}},{"id":1360616,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2024-11-19T21:20:06.000Z","date":"2024-11-15","kind":"exercise","planned":true,"acquired":false,"shares":2969,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":26719,"derivative":{"underlying":"Common Stock","underlying_shares":2969},"source":{"system":"sec-edgar","filing":"0000950170-24-128626","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000095017024128626/ownership.xml","form_type":"4"}},{"id":1360615,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-11-19T21:20:06.000Z","date":"2024-11-18","kind":"sale","planned":true,"acquired":false,"shares":977,"price":0.5407,"value":528.2639,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 11, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.5406 to $0.5442, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":32415,"source":{"system":"sec-edgar","filing":"0000950170-24-128626","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000095017024128626/ownership.xml","form_type":"4"}},{"id":1360614,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-11-19T21:20:06.000Z","date":"2024-11-15","kind":"exercise","planned":true,"acquired":true,"shares":2969,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":33392,"source":{"system":"sec-edgar","filing":"0000950170-24-128626","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000095017024128626/ownership.xml","form_type":"4"}},{"id":1380400,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2024-10-29T22:33:30.000Z","date":"2024-10-27","kind":"exercise","planned":true,"acquired":false,"shares":13744,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 3, 2023, the reporting person was granted an award of 27,489 restricted stock units (\"RSUs\"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the \"Initial Milestone Date\"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,745 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 13,744 RSUs vested and settled on October 27, 2024, the date that was eighteen months from the Initial Milestone Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":13744},"source":{"system":"sec-edgar","filing":"0000950170-24-118424","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000095017024118424/ownership.xml","form_type":"4"}},{"id":1380399,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-10-29T22:33:30.000Z","date":"2024-10-28","kind":"sale","planned":true,"acquired":false,"shares":4334,"price":0.6902,"value":2991.3268,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on July 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.69 to $ 0.7011, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":30423,"source":{"system":"sec-edgar","filing":"0000950170-24-118424","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000095017024118424/ownership.xml","form_type":"4"}},{"id":1380398,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-10-29T22:33:30.000Z","date":"2024-10-27","kind":"exercise","planned":true,"acquired":true,"shares":13744,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 3, 2023, the reporting person was granted an award of 27,489 restricted stock units (\"RSUs\"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the \"Initial Milestone Date\"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,745 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 13,744 RSUs vested and settled on October 27, 2024, the date that was eighteen months from the Initial Milestone Date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date."}],"balance_after":34757,"source":{"system":"sec-edgar","filing":"0000950170-24-118424","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000095017024118424/ownership.xml","form_type":"4"}},{"id":1430365,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2024-08-19T21:45:53.000Z","date":"2024-08-15","kind":"exercise","planned":true,"acquired":false,"shares":2969,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":29688,"derivative":{"underlying":"Common Stock","underlying_shares":2969},"source":{"system":"sec-edgar","filing":"0000950170-24-098717","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000095017024098717/ownership.xml","form_type":"4"}},{"id":1430364,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-08-19T21:45:53.000Z","date":"2024-08-16","kind":"sale","planned":true,"acquired":false,"shares":973,"price":0.84,"value":817.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 11, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.8414 to $0.890001, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":21013,"source":{"system":"sec-edgar","filing":"0000950170-24-098717","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000095017024098717/ownership.xml","form_type":"4"}},{"id":1430363,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-08-19T21:45:53.000Z","date":"2024-08-15","kind":"exercise","planned":true,"acquired":true,"shares":2969,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":21986,"source":{"system":"sec-edgar","filing":"0000950170-24-098717","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000095017024098717/ownership.xml","form_type":"4"}},{"id":1489098,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T20:26:51.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":195000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date."}],"balance_after":195000,"derivative":{"exercise_price":0.664,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":195000},"source":{"system":"sec-edgar","filing":"0001415889-24-015763","document":"form4-06062024_080647.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000141588924015763/form4-06062024_080647.xml","form_type":"4"}},{"id":1489097,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-06T20:26:51.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":150647,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares underlying restricted stock units (\"RSUs\") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date."}],"balance_after":183009,"source":{"system":"sec-edgar","filing":"0001415889-24-015763","document":"form4-06062024_080647.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000141588924015763/form4-06062024_080647.xml","form_type":"4"}},{"id":1513045,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2024-05-18T00:23:05.000Z","date":"2024-05-15","kind":"exercise","planned":true,"acquired":false,"shares":2968,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":32657,"derivative":{"underlying":"Common Stock","underlying_shares":2968},"source":{"system":"sec-edgar","filing":"0000950170-24-062061","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000095017024062061/ownership.xml","form_type":"4"}},{"id":1513044,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-05-18T00:23:05.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":939,"price":0.94,"value":882.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 11, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.94 to $0.943, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":19017,"source":{"system":"sec-edgar","filing":"0000950170-24-062061","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000095017024062061/ownership.xml","form_type":"4"}},{"id":1513043,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-05-18T00:23:05.000Z","date":"2024-05-15","kind":"exercise","planned":true,"acquired":true,"shares":2968,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":19956,"source":{"system":"sec-edgar","filing":"0000950170-24-062061","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000095017024062061/ownership.xml","form_type":"4"}},{"id":1639867,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2024-02-17T02:21:40.000Z","date":"2024-02-15","kind":"exercise","planned":true,"acquired":false,"shares":11875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":35625,"derivative":{"underlying":"Common Stock","underlying_shares":11875},"source":{"system":"sec-edgar","filing":"0000950170-24-016690","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000095017024016690/ownership.xml","form_type":"4"}},{"id":1639866,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2024-02-17T02:21:40.000Z","date":"2024-02-14","kind":"grant","planned":true,"acquired":true,"shares":35625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date."}],"balance_after":35625,"derivative":{"underlying":"Common Stock","underlying_shares":35625},"source":{"system":"sec-edgar","filing":"0000950170-24-016690","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000095017024016690/ownership.xml","form_type":"4"}},{"id":1639865,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-17T02:21:40.000Z","date":"2024-02-14","kind":"grant","planned":true,"acquired":true,"shares":287905,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option will vest, if at all, in two substantially equal installments upon achievement of a 30-day trailing average public market closing price per share of the Issuer's common stock greater than or equal to $3.00 and $5.00, respectively."}],"balance_after":287905,"derivative":{"exercise_price":1.1,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":287905},"source":{"system":"sec-edgar","filing":"0000950170-24-016690","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000095017024016690/ownership.xml","form_type":"4"}},{"id":1639864,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-17T02:21:40.000Z","date":"2024-02-14","kind":"grant","planned":true,"acquired":true,"shares":213750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option will vest as to 25% of the shares on February 14, 2025. The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":213750,"derivative":{"exercise_price":1.1,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":213750},"source":{"system":"sec-edgar","filing":"0000950170-24-016690","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000095017024016690/ownership.xml","form_type":"4"}},{"id":1639863,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-02-17T02:21:40.000Z","date":"2024-02-16","kind":"sale","planned":true,"acquired":false,"shares":4400,"price":1.08,"value":4752.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 11, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average of the price.  These shares were sold in multiple transactions at prices ranging from $1.08 to $1.115, inclusive.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":16988,"source":{"system":"sec-edgar","filing":"0000950170-24-016690","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000095017024016690/ownership.xml","form_type":"4"}},{"id":1639862,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-02-17T02:21:40.000Z","date":"2024-02-15","kind":"exercise","planned":true,"acquired":true,"shares":11875,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":21388,"source":{"system":"sec-edgar","filing":"0000950170-24-016690","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000095017024016690/ownership.xml","form_type":"4"}},{"id":1753555,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2023-11-01T01:36:59.000Z","date":"2023-10-27","kind":"exercise","planned":true,"acquired":false,"shares":13745,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each RSU represents a contingent right to receive one share of Issuer common stock.  The RSUs do not have an expiration date."},{"field":"shares","element":"transactionShares","label":"F1","text":"On February 3, 2023, the reporting person was granted an award of 27,489 restricted stock units (\"RSUs\"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria.  On April 27, 2023 (the \"Initial Milestone Date\"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,745 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 13,744 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 3, 2023, the reporting person was granted an award of 27,489 restricted stock units (\"RSUs\"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria.  On April 27, 2023 (the \"Initial Milestone Date\"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,745 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 13,744 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each RSU represents a contingent right to receive one share of Issuer common stock.  The RSUs do not have an expiration date."}],"balance_after":13744,"derivative":{"underlying":"Common Stock","underlying_shares":13745},"source":{"system":"sec-edgar","filing":"0000899243-23-020070","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000089924323020070/doc4.xml","form_type":"4"}},{"id":1753554,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2023-11-01T01:36:59.000Z","date":"2023-04-27","kind":"grant","planned":true,"acquired":true,"shares":27489,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each RSU represents a contingent right to receive one share of Issuer common stock.  The RSUs do not have an expiration date."},{"field":"shares","element":"transactionShares","label":"F1","text":"On February 3, 2023, the reporting person was granted an award of 27,489 restricted stock units (\"RSUs\"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria.  On April 27, 2023 (the \"Initial Milestone Date\"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,745 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 13,744 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 3, 2023, the reporting person was granted an award of 27,489 restricted stock units (\"RSUs\"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria.  On April 27, 2023 (the \"Initial Milestone Date\"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,745 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 13,744 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each RSU represents a contingent right to receive one share of Issuer common stock.  The RSUs do not have an expiration date."}],"balance_after":27489,"derivative":{"underlying":"Common Stock","underlying_shares":27489},"source":{"system":"sec-edgar","filing":"0000899243-23-020070","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000089924323020070/doc4.xml","form_type":"4"}},{"id":1753553,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-11-01T01:36:59.000Z","date":"2023-10-30","kind":"sale","planned":true,"acquired":false,"shares":4232,"price":1.35,"value":5713.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on July 2, 2023, solely with the intent to cover taxes in connection with the vesting of the RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average of the price.  These shares were sold in multiple transactions at prices ranging from $1.3406 to $1.4115, inclusive.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":9513,"source":{"system":"sec-edgar","filing":"0000899243-23-020070","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000089924323020070/doc4.xml","form_type":"4"}},{"id":1753552,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-11-01T01:36:59.000Z","date":"2023-10-27","kind":"exercise","planned":true,"acquired":true,"shares":13745,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 3, 2023, the reporting person was granted an award of 27,489 restricted stock units (\"RSUs\"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria.  On April 27, 2023 (the \"Initial Milestone Date\"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,745 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 13,744 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date."}],"balance_after":13745,"source":{"system":"sec-edgar","filing":"0000899243-23-020070","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000089924323020070/doc4.xml","form_type":"4"}},{"id":1868337,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-05T20:36:25.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":44961,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 1, 2024 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date."}],"balance_after":44961,"derivative":{"exercise_price":3.09,"expiration_date":"2033-06-01","underlying":"Common Stock","underlying_shares":44961},"source":{"system":"sec-edgar","filing":"0001209191-23-034341","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000120919123034341/doc4.xml","form_type":"4"}},{"id":1868336,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-05T20:36:25.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":32362,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares underlying restricted stock units (\"RSUs\") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest  on the earlier of (i) June 1, 2024 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date."}],"balance_after":32362,"source":{"system":"sec-edgar","filing":"0001209191-23-034341","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000120919123034341/doc4.xml","form_type":"4"}},{"id":2029592,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-07T22:48:39.000Z","date":"2023-02-03","kind":"grant","acquired":true,"shares":95000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option will vest as to 25% of the shares on February 3, 2024. The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":95000,"derivative":{"exercise_price":5.5,"expiration_date":"2033-02-02","underlying":"Common Stock","underlying_shares":95000},"source":{"system":"sec-edgar","filing":"0000899243-23-004210","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000089924323004210/doc4.xml","form_type":"4"}},{"id":2029591,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2023-02-07T22:48:39.000Z","date":"2023-02-03","kind":"grant","acquired":true,"shares":47500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter."}],"balance_after":47500,"derivative":{"underlying":"Common Stock","underlying_shares":47500},"source":{"system":"sec-edgar","filing":"0000899243-23-004210","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000089924323004210/doc4.xml","form_type":"4"}},{"id":2051662,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-19T22:49:46.000Z","date":"2023-01-02","kind":"grant","acquired":true,"shares":45841,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares shall vest and become exercisable in twelve (12) equal quarterly installments beginning on November 1, 2022, in each case subject to the Reporting Person's continued service as of each such date."}],"balance_after":45841,"derivative":{"exercise_price":10.74,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":45841},"source":{"system":"sec-edgar","filing":"0001209191-23-004068","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000120919123004068/doc4.xml","form_type":"4"}},{"id":2409261,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-09T02:30:43.000Z","date":"2022-02-04","kind":"grant","acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 25% of the shares on February 4, 2023. The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":175000,"derivative":{"exercise_price":7.38,"expiration_date":"2032-02-03","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0000899243-22-005317","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000089924322005317/doc4.xml","form_type":"4"}},{"id":2875516,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-08T23:53:16.000Z","date":"2021-02-04","kind":"grant","acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 25% of the shares on February 4, 2022. The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":110000,"derivative":{"exercise_price":26.34,"expiration_date":"2031-02-03","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0000899243-21-005250","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000089924321005250/doc4.xml","form_type":"4"}},{"id":3181143,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":37467,"kind":"person","name":"von Moltke Lisa","position":1,"cik":"0001808592","reported_name":"von Moltke Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-07T20:18:49.000Z","date":"2020-04-06","kind":"grant","acquired":true,"shares":325000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 25% of the underlying shares on the first anniversary of April 6, 2020 and as to an additional 6.25% upon the completion of each three-month period of continuous service to the company thereafter."}],"balance_after":325000,"derivative":{"exercise_price":3.32,"expiration_date":"2030-04-05","underlying":"Common Stock","underlying_shares":325000},"source":{"system":"sec-edgar","filing":"0000899243-20-010407","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808592/000089924320010407/doc4.xml","form_type":"4"}}]}